Kiora Pharmaceuticals (FRA:7EY) NonCurrent Deferred Liabilities: €1.17 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7EY Kiora Pharmaceuticals Inc FRA:7EY
33 GF Score
Price €0.42
! 3 Warning Signs
View Full Analysis

What is Kiora Pharmaceuticals NonCurrent Deferred Liabilities?

Kiora Pharmaceuticals FRA:7EY 33 NonCurrent Deferred Liabilities is €1.17 Mil as of Mar. 2026. GuruFocus rates FRA:7EY with a GF Score™ of 33/100. The stock has 3 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Kiora Pharmaceuticals's non-current deferred liabilities for the quarter that ended in Mar. 2026 was €1.17 Mil.

Kiora Pharmaceuticals NonCurrent Deferred Liabilities Related Terms

Kiora Pharmaceuticals NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Kiora Pharmaceuticals's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiora Pharmaceuticals NonCurrent Deferred Liabilities Chart

Kiora Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.71 0.65 0.71 0.47 1.16

Kiora Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 1.51 1.48 1.16 1.17
FRA:7EY
33GF Score
Kiora Pharmaceuticals Inc FRA:7EY
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of €1.17 Mil mean?
Kiora Pharmaceuticals (FRA:7EY) has a NonCurrent Deferred Liabilities of €1.17 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Kiora Pharmaceuticals and its competitors.
Is Kiora Pharmaceuticals' NonCurrent Deferred Liabilities too high?
Kiora Pharmaceuticals' current NonCurrent Deferred Liabilities is €1.17 Mil. Overall, Kiora Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Kiora Pharmaceuticals' NonCurrent Deferred Liabilities compare to PHIO and PBM?
Kiora Pharmaceuticals' NonCurrent Deferred Liabilities of €1.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Kiora Pharmaceuticals and its competitors. Kiora Pharmaceuticals's current NonCurrent Deferred Liabilities is €1.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiora Pharmaceuticals stock overvalued right now?
Kiora Pharmaceuticals (FRA:7EY) has a current NonCurrent Deferred Liabilities of €1.17 Mil. The current NonCurrent Deferred Liabilities is €1.17 Mil. Kiora Pharmaceuticals' overall GF Score™ is 33/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Kiora Pharmaceuticals (FRA:7EY), the current NonCurrent Deferred Liabilities is €1.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kiora Pharmaceuticals Business Description

Other Exchanges KPRX:USA
Address 169 Saxony Road, Suite 212, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
33GF Score

Get the complete analysis for FRA:7EY

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.42
Price